Status:

RECRUITING

Clinical and Molecular Features of Oral Premalignancy and Oral Cancer

Lead Sponsor:

M.D. Anderson Cancer Center

Conditions:

Oral Cancer

Eligibility:

All Genders

18+ years

Brief Summary

Investigators will employ serial assessments of tissue biopsy and additional biomarkers that reflect burden of disease and predict treatment response. Patients enrolled on this study will be given the...

Detailed Description

Primary objectives: Current primary objectives need revision as they focus on diabetes which is not the focus of this study. * Investigators will examine the role of clinical, environmental, and gene...

Eligibility Criteria

Inclusion

  • Aged 18 or older, with a diagnosis of oral premalignant or malignant tumors (eligible diagnoses listed below) or presenting with suspected premalignant or malignant tumors for definitive diagnosis
  • Must be able to provide informed consent
  • Oral premalignant or malignant tumors presenting for evaluation for the first time at UT MD Anderson Cancer Center
  • Oral premalignant or malignant tumors who were previously treated or evaluated at UT MD Anderson Cancer Center who presents for evaluation of progressive or recurrent disease. Newly collected biospecimens and tissue samples will be linked to applicable samples previously collected and banked/stored under PA17-0050, LAB02-427, Lab02-039 and Lab08-0848.
  • Eligible diagnoses include:
  • Leukoplakia
  • Erythroplakia
  • Mild dysplasia
  • Moderate dysplasia
  • Severe dysplasia
  • Carcinoma in situ
  • Squamous cell carcinoma
  • Exclusion:
  • \- Pregnant women and/or cognitively-impaired adults are excluded from this study.
  • Exclusion Criteria:
  • \- Prior oral squamous cell carcinoma (OSCC) surgery or OSCC radiation treatment at a non-MDA institution.

Exclusion

    Key Trial Info

    Start Date :

    October 31 2024

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 31 2066

    Estimated Enrollment :

    1000 Patients enrolled

    Trial Details

    Trial ID

    NCT06550050

    Start Date

    October 31 2024

    End Date

    December 31 2066

    Last Update

    October 24 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    MD Anderson Cancer Center

    Houston, Texas, United States, 77030